This Startup Could Detect Pregnancy Risks Before Symptoms Appear

Jan de Vries · 2026-09-02

Here's a story about a quiet revolution in prenatal care. iPremom, a molecular diagnostics company from Valencia, Spain, just secured $16.2 million in Seed funding. They're tackling a problem that's been overlooked for too long: predicting pregnancy complications far earlier than anyone thought possible. Their secret weapon is the MaiRa platform. It’s a blood test that analyzes molecular signals in the first trimester—long before any clinical signs show up. The goal is to give expecting mothers and their doctors a head start, turning reactive care into proactive prevention. ### The Funding Behind the Vision The $16.2 million round was led by Amadeus Capital Partners, with Asabys Partners and APEX Ventures also joining in. For the team at iPremom, this isn't just about money. It's validation for a decade of research and a critical step toward bringing their technology to clinics worldwide. Professor Carlos Simón, co-founder and Chairman, put it perfectly. He says pregnancy complications have been under-diagnosed for generations because medicine was "looking in the wrong place at the wrong time." His ambition isn't just a better test. It's about giving every pregnant woman a comprehensive, early molecular picture of her pregnancy. ### A Surge in European HealthTech Investment This funding didn't happen in a vacuum. There's been a noticeable flow of capital into European molecular diagnostics and women's health this year. Think about it: - En Carta Diagnostics in Paris raised about $5.4 million for at-home molecular testing. - Germany's Intu Diagnostics secured nearly $1.2 million, focusing initially on HPV testing. - Zurich-based KOVE Medical got roughly $1.8 million to reduce preterm-birth risks. - Menstrual-health company DITTO raised approximately $5.6 million. AI-driven diagnostics are also heating up, with companies like Moonlight AI and preventive-health platform Lucis pulling in significant funding. In Spain, iPremom's closest peer might be Barcelona's Health Lean Analytics, which raised over $2.3 million for hospital-focused tech. ### How the MaiRa Platform Actually Works So, what makes this different? It's built on more than a decade of work by Prof. Simón and Dr. Tamara Garrido, the Chief Scientific Officer. Their research revealed that molecular signals for complications like preeclampsia leave a trace in maternal blood incredibly early—between 9 to 14 weeks into pregnancy. The science hinges on something called decidualisation resistance. In simple terms, it's when the uterine lining doesn't develop as expected. This process leaves a detectable marker, cell-free RNA (cfRNA), circulating in the blood. The MaiRa platform analyzes a single blood sample for these cfRNA signals and uses AI-powered predictive models to assess risk months before any symptoms arise. ### Built on Real-World Data You can't build this on theory alone. The platform's models are trained on a massive, real-world dataset from one of Spain's largest prospective clinical trials, the PREMOM study. We're talking about data from over 26,000 samples linked to 10,000 pregnancies. That foundation is already helping them identify signals for an even broader range of complications to add to the platform. Pierre Socha from Amadeus Capital Partners highlighted why they backed this vision. They'd previously partnered with Prof. Simón on Igenomix, which transformed IVF genetics. They believe iPremom is poised to do the same for prenatal care—a market that's even larger. By predicting risk from the first weeks with a simple blood test, it could prepare millions of expecting couples and give clinicians powerful tools for early intervention. Founded in 2019, iPremom sits at the intersection of MedTech, molecular diagnostics, and AI. Their progress is a sign of a bigger shift—where healthcare stops waiting for problems to emerge and starts preventing them from the very beginning.